Introduction
Research goals
The national program on psoriasis care was based on the following questions
Methods
CVderm 2005–2015 | National health care goals addressed | |||||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
Study | Topic | QoL | PsA | Com. | Childr. | HSR |
PsoAdhere | Identification and training of adherence in patients with psoriasis | x | ||||
PsoAMNOG | Evaluation of the German AMNOG drug assessment | x | ||||
PsoArt | Screening on psoriatic arthritis | x | ||||
PsoBarrier | Exploration of barriers for guideline-compliant health care in psoriasis and development of strategies | x | x | x | x | |
PsoBest | The German Psoriasis Registry | x | x | x | ||
PsoBest-kid | The German Psoriasis Registry, module for children | x | x | x | ||
PsoCare 1 + 2 | SHI health care study on children with psoriasis and atopic eczema | x | x | x | x | |
PsoCare 3 + 4 | SHI health care study on adults with psoriasis and atopic eczema | x | x | x | x | |
PsoCity | Psoriasis in the population-based Hamburg City Health Study | x | x | x | x | |
PsoCom | Standards and effectiveness of screening for comorbidity | x | ||||
PsoComp | Patient-relevant endpoints in psoriasis | x | x | |||
PsoCort | Use of corticosteroids in psoriasis: Metaanalysis | x | x | |||
PsoCost | Cost-of-illness and budget impact in psoriasis | x | x | |||
PsoDrop | Analysis of drug survival and persistance in real-world therapy for psoriasis (data from PsoBest) | x | x | x | x | |
PsoOdyssee | Development and application of a comprehensive modeling system to predict and quantify processes and outcomes on a national level | x | x | x | x | |
PsoEpi | Epidemiology of psoriasis in Germany | x | x | |||
PsoEU | Evaluation of the psoriasis health care structures, processes and quality in Europe: Survey in 38 countries | x | x | x | x | x |
PsoGoal | Effectiveness of treatment goals in psoriasis | x | x | x | x | x |
PsoGuide | Hurdles of guideline-compliant treatment of psoriasis in Germany | x | x | x | x | |
PsoHarm | Methods for identifying patient harm in systemic treatment | x | x | |||
PsoHead | Prevalence of scalp psoriasis in Germany | x | x | |||
PsoHealth 1–3 | National health care studies for psoriasis 2005, 2007, 2014 | x | x | |||
PsoKid | Psoriasis health care in children | x | ||||
PsoLife | Long-term drug survival in psoriasis | x | x | |||
PsoLong | Characteristics of topical long-term treatment for psoriasis in German routine care | x | x | |||
PsoMetrics | Outcomes, measurement and treatment goals in psoriasis | x | ||||
PsoMod | Modelling of long-term course of psoriasis and psoriatic artrithis | x | x | x | x | |
PsoNet | German Psoriasis Networks | x | x | x | ||
PsoPharm | National health care studies for psoriasis in pharmacies 2009 | x | x | x | x | |
PsoPlus | Benefits of membership in a psoriasis patient advocacy group: RCT | x | x | |||
PsoPrefer | Patient preferences in psoriasis therapy | x | x | |||
PsoPRO | Methodology of patient outcomes measurements | x | x | x | x | |
PsoRapid | Optimising time to responds in psoriasis treatment | x | x | x | ||
PsoReal | Health-care from the perspective of patient groups in Germany | x | x | |||
PsoSat | Patient satisfaction and treatment optimization | x | ||||
PsoSpecial | Benefits of psoriasis care in a specialized center | x | x | |||
PsoTility | Optimizing use of utility measures in psoriasis | x | x | |||
PsoTop | Topology of psoriasis | x | x | x | ||
PsoVac | Vaccinations in systemic therapies for psoriasis | x | x | x | x | |
PsoWeb | Web-based health care studies in psoriasis | x | x | x | x | |
PsoWork | Impact of psoriasis on work productivity | x | x | x |
Results
Measuring prevalence, disease burden, quality and outcomes of health care for psoriasis
-
Prevalence of psoriasis
-
Patient relevance (patient burden)
-
Clinical relevance (health care consumption)
-
Economic impact
-
Potential for prevention
-
Quality of health care
-
Guidelines (availability, use, compliance)
-
Access to health care
-
Benefits of treatments
-
Efficiency of health care
-
Gaps and under-/overprovision of care
-
Barriers of health care
Identifying the prevalence of psoriasis in Germany
-
Analysis of sick fund (claims) data
-
Population-based surveys
-
Web-based surveys
Measuring disease burden
Costs of psoriasis
Identification of patient needs
Definition of health care needs
Measuring quality of health care and guideline compliance
Evaluating access to psoriasis health care and treatment variations
Intervention program for improving health care in psoriasis
Development and implementation of guidelines
Patient empowerment
National Conference on Health Care in Psoriasis and National Health Care Goals in Psoriasis 2010–2015
Introduction of outcomes tools and treatment goals
Development of regional psoriasis networks: PsoNet
Improved patient safety: The German Psoriasis Registry PsoBest
Identification of barriers
Awareness program: World Psoriasis Day
Certification on quality in psoriasis care
Dissemination of health care data
Evaluation program for improvement of health care in psoriasis
Indicator | PsoHealth1 (2005) | PsoHealth2 (2007) | PsoHealth3 (2013/14) | Goal by end of 2015 [56] | Trend 2005–2014 |
---|---|---|---|---|---|
n | 1511 | 2009 | 1258 | ||
Mean PASI | 11.4 | 10.1 | 8.1 | <8.0 | +a
|
Mean DLQI | 8.6 | 7.5 | 5.9 | <6.0 | ++b
|
% PASI >20 | 17.8 % | 11.6 % | 9.2 % | <10 % | ++ |
% DLQI >10 | 34.0 % | 28.2 % | 21.3 % | <15 % | + |
% With previous systemic treatment | 32.9 % | 47.3 % | 59.5 % | >65 % | + |
% Hospital treatment (past 5 years) | 26.9 % | 20.1 % | 20.1 % | <15 % | (+)c
|
Mean number of days absent from work | 4.9 | 4.0 | 3.5 | <3.0 | + |